Mester S, Chan C, Lustig M, Foss S, Jansen J, Leangen Herigstad M
PNAS Nexus. 2025; 4(2):pgaf042.
PMID: 40041621
PMC: 11878800.
DOI: 10.1093/pnasnexus/pgaf042.
Devanaboyina S, Li P, LaGory E, Poon-Andersen C, Cook K, Soto M
MAbs. 2024; 16(1):2383013.
PMID: 39051531
PMC: 11275528.
DOI: 10.1080/19420862.2024.2383013.
Mullin M, McClory J, Haynes W, Grace J, Robertson N, van Heeke G
MAbs. 2024; 16(1):2341443.
PMID: 38666503
PMC: 11057648.
DOI: 10.1080/19420862.2024.2341443.
Bernardim B, Conde J, Hakala T, Becher J, Canzano M, Vasco A
Bioconjug Chem. 2024; 35(2):132-139.
PMID: 38345213
PMC: 10885003.
DOI: 10.1021/acs.bioconjchem.3c00478.
Dinesen A, Andersen V, Elkhashab M, Pilati D, Bech P, Fuchs E
Bioconjug Chem. 2024; 35(2):214-222.
PMID: 38231391
PMC: 10886128.
DOI: 10.1021/acs.bioconjchem.3c00491.
A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.
Benjakul S, Anthi A, Kolderup A, Vaysburd M, Lode H, Mallery D
PNAS Nexus. 2023; 2(12):pgad403.
PMID: 38077689
PMC: 10703496.
DOI: 10.1093/pnasnexus/pgad403.
SARS-CoV-2 spike protein S1 subunit induces potent neutralizing responses in mice and is effective against Delta and Omicron variants.
Mamedov T, Yuksel D, Gurbuzaslan I, Gulec B, Mammadova G, Ozdarendeli A
Front Plant Sci. 2023; 14:1290042.
PMID: 38034565
PMC: 10682712.
DOI: 10.3389/fpls.2023.1290042.
Development of an Albumin-Masked mutPD-1Ig as a Tumor Lesion-Selective Immune Checkpoint Inhibitor.
Chou C, Li Z, Huang H, Hung C, Weng S, Tzou S
ACS Omega. 2023; 8(43):40911-40920.
PMID: 37929112
PMC: 10621011.
DOI: 10.1021/acsomega.3c06216.
Recent Advancements and Strategies for Overcoming the Blood-Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma.
Tincu Iurciuc C, Andritoiu C, Popa M, Ochiuz L
Polymers (Basel). 2023; 15(19).
PMID: 37836018
PMC: 10575401.
DOI: 10.3390/polym15193969.
1,4-Naphthoquinone Induces FcRn Protein Expression and Albumin Recycling in Human THP-1 Cells.
Esawi E, Mahmoud I, Abdullah M, Abuarqoub D, Ahram M, Alshaer W
ACS Omega. 2023; 8(18):16491-16499.
PMID: 37179634
PMC: 10173444.
DOI: 10.1021/acsomega.3c01678.
Human arginase I: a potential broad-spectrum anti-cancer agent.
Anakha J, Prasad Y, Sharma N, Pande A
3 Biotech. 2023; 13(5):159.
PMID: 37152001
PMC: 10156892.
DOI: 10.1007/s13205-023-03590-3.
Assessing developability early in the discovery process for novel biologics.
Fernandez-Quintero M, Ljungars A, Waibl F, Greiff V, Andersen J, Gjolberg T
MAbs. 2023; 15(1):2171248.
PMID: 36823021
PMC: 9980699.
DOI: 10.1080/19420862.2023.2171248.
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
Tapia-Galisteo A, Compte M, Alvarez-Vallina L, Sanz L
Theranostics. 2023; 13(3):1028-1041.
PMID: 36793863
PMC: 9925307.
DOI: 10.7150/thno.81494.
Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.
Bradford H, Haljasmagi L, Menon M, McDonnell T, Sarekannu K, Vanker M
Cell Rep Med. 2023; 4(1):100894.
PMID: 36652906
PMC: 9873953.
DOI: 10.1016/j.xcrm.2022.100894.
Species Differences in Tryptophan Metabolism and Disposition.
Badawy A, Guillemin G
Int J Tryptophan Res. 2022; 15:11786469221122511.
PMID: 36325027
PMC: 9620070.
DOI: 10.1177/11786469221122511.
A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies.
Zhang Z, Yan Y, Wang S, Li N
MAbs. 2022; 14(1):2133674.
PMID: 36224723
PMC: 9559042.
DOI: 10.1080/19420862.2022.2133674.
Human arginase 1, a Jack of all trades?.
Anakha J, Kawathe P, Datta S, Jawalekar S, Banerjee U, Pande A
3 Biotech. 2022; 12(10):264.
PMID: 36082360
PMC: 9450830.
DOI: 10.1007/s13205-022-03326-9.
Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.
Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup O
iScience. 2022; 25(9):104958.
PMID: 36072551
PMC: 9441337.
DOI: 10.1016/j.isci.2022.104958.
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo J
Cancer Chemother Pharmacol. 2022; 89(4):499-514.
PMID: 35298698
PMC: 8956549.
DOI: 10.1007/s00280-022-04414-6.
Soluble Human Angiotensin- Converting Enzyme 2 as a Potential Therapeutic Tool for COVID-19 is Produced at High Levels In Plant With Potent Anti-SARS-CoV-2 Activity.
Mamedov T, Gurbuzaslan I, Yuksel D, Ilgin M, Mammadova G, Ozkul A
Front Plant Sci. 2021; 12:742875.
PMID: 34938305
PMC: 8685454.
DOI: 10.3389/fpls.2021.742875.